AI주식인사이트AI Stock Insight
C

경남제약

053950KOSDAQ의약품 제조업

50.5 / 100

Reference Date: 2026-06-10

Financial Score20.0 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 41.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongnam Pharmaceutical primarily operates in the manufacturing and sales of pharmaceuticals, raw materials, and health functional foods, distributing products like Lemona, Jaha Saengryeok, and Minol. In 2025, revenue reached 55.9 billion won, a decrease of approximately 8% compared to the previous period, though the Lemona food product line continues to show steady growth. The company is expanding its business through online marketing and broadening its distribution channels.

Number of Employees

238people

Average Salary

53.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.934.0Point
PBR
0.28Industry Average 0.897.0Point

Half of industry avg (excellent)

ROE
-8.06Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
1.01Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼9.6% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲1.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -7.9% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 2Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position5.0Point

52w mid range (50%)

Current 1,965Won52-week high 3,35052-week low 564
1-month return0.0Point

1m -41.34% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 1Neutral 6Negative 0
  • Neutral정정신고서제출요구( 2026.05.21. 제출 증권신고서(지분증권) )2026-06-08
  • Neutral임시주주총회결과2026-05-26
  • Neutral주주명부폐쇄기간또는기준일설정2026-05-21
  • Neutral증권신고서(지분증권)2026-05-21
  • Positive주요사항보고서(유상증자결정)2026-05-21